Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy  + (Oral 100mg/day from first day of chemotherapy, daily)
• Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial  + (Oral 400mg twice daily (immediately before radiotherapy and 8-12 hours after) Start: Day 0 radiotherapy Duration: entire radiotherapy)
• Ferreira et al. (2004): Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: A double-blind randomized trial  + (Oral 500mg twice daily (immediately before radiotherapy and 8-12 hours after) Start: Day 0 radiotherapy Duration: entire radiotherapy)
• Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial  + (Oral capsules of calcitriol 0.25 μg, three times daily from day 0 to 30)
• Raoufinejad et al. (2019): Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial  + (Oral capsules of placebo (identical to the calcitriol for color, shape, size, taste, and smell), three times daily from day 0 to 30)
• Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer  + (Oral capsules with tapioca powder)
• Braik et al. (2014): Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy  + (Oral from first day of chemotherapy, daily)
• Crew et al. (2012): Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer  + (Oral green tea extract with 400mg EGCG twice daily for 6 month)
• Crew et al. (2012): Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer  + (Oral green tea extract with 600mg EGCG twice daily for 6 month)
• Crew et al. (2012): Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer  + (Oral green tea extract with 800mg EGCG twice daily for 6 month)
• Tan et al. (2018): Bromelain has significant clinical benefits after extraction of the third molar during chemotherapy in patients with hematologic tumor  + (Oral intake of 3 x 30,000 units of enteric-coated capsules of bromelain daily, starting one day before the surgery up to and including three days after the surgery + all patients: sugery: third molar extraction was performed under local anesthesia)
• Johansson et al. (2021): Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial  + (Oral solution in ampoule containing 100,000 IU of vitamin D3 (an average of 2000 IU/day), every 50 days, for 3 years)
• Johansson et al. (2021): Vitamin D Supplementation and Disease-Free Survival in Stage II Melanoma: A Randomized Placebo Controlled Trial  + (Oral solution in ampoule containing placebo, every 50 days, for 3 years)
• Lichtmann et al. (2018): Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain  + (Oral spray (self-applied by patient) Week 1: dose finding; week 2-5: stable dose, maximum 10 sprays Mean number of spray bursts in the 1st week: 3.8 and then stabilized: 7.3)
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (Oral syrup of an elemental zinc at a concentration of 5 mg per cc, self-administered at 10 cc per meal, three times a day at meal times, Duration: on the first day of radiation and to continue daily including weekends until the completion of radiation)
• Sangthawan et al. (2015): Effects of zinc sulfate supplementation on cell-mediated immune response in head and neck cancer patients treated with radiation therapy  + (Oral syrup that consisted of elemental zin … Oral syrup that consisted of elemental zinc at a concentration of 5 mg per cc, self-administered at 50 mg (10 cc) per meal, 3 times a day at meal times,</br>Duration: on the first day of radiation and continue daily, including weekends, until the completion of radiationeekends, until the completion of radiation)
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (Oral syrup, identical in taste and consistency, self-administered at 10 cc per meal, three times a day at meal times, Duration: on the first day of radiation and to continue daily including weekends until the completion of radiation)
• Sangthawan et al. (2015): Effects of zinc sulfate supplementation on cell-mediated immune response in head and neck cancer patients treated with radiation therapy  + (Oral syrup, identical in taste and consistency, self-administered at 10 cc per meal, three times a day at meal times, Duration: on the first day of radiation and continue daily, including weekends, until the completion of radiation)
• Jyothirmayi et al. (1996): Efficacy of Vitamin A in the Prevention of Locoregional Recurrence and Second Primaries in Head and Neck Cancer  + (Oral vitamin A 200,000 IU per week as chewable tablets of retinyl palmitate)
• Lin et al. (2006): Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers: a double-blind, randomized study  + (Oral zinc (25 mg Pro-Z), three capsules per day)
• Lin et al. (2008): Effects of zinc supplementation on clinical outcomes in patients receiving radiotherapy for head and neck cancers: a double-blinded randomized study  + (Oral zinc (25 mg Pro-Z), three capsules per day)
• Lin et al. (2009): Effects of zinc supplementation on the survival of patients who received concomitant chemotherapy and radiotherapy for advanced nasopharyngeal carcinoma: follow-up of a double-blind randomized study with subgroup analysis  + (Oral zinc (25 mg Pro-Z), three capsules per day)
• Lin et al. (2010): Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers: subgroup analysis of a double-blind, randomized study  + (Oral zinc (25 mg Pro-Z), three capsules per day)
• Upadhyaya et al. (2017): Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differential thyroid cancer: A randomized-controlled trial  + (Oral, 100mg Duration: week -1 radioiodine treatment until week +4 (total 5 weeks))
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Oral, 2.2g EPA daily + 2g/daily Resource Support Duration: 4 month)

• Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study  + (Oral, 2.5mg 2 times a day + liquid placebo)

• Upadhyaya et al. (2017): Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differential thyroid cancer: A randomized-controlled trial  + (Oral, 200mg Duration: week -1 radioiodine treatment until week +4 (total 5 weeks))
• Ota et al. (2014): The effect of pyridoxine for prevention of hand-foot-syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine: A randomized study  + (Oral, 20mg 3 times daily)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Oral, 2x 100mg daily Duration: 4 month)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Oral, 2x 2g daily Duration: 4 month)
• Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation  + (Oral, 2x daily Start: day -7 surgery Duration: until day 28 after surgery)
• Sun et al. (2016): A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy  + (Oral, 3 x 1000 mg daily (in two 500 mg tablets) Duration: 8 weeks)
• Okabayashi et al. (2020): L-Carnitine Improves Postoperative Liver Function in Hepatectomized Patients  + (Oral, 30 mg/kg body weight for 2 weeks before surgery)
• Upadhyaya et al. (2017): Radioprotective effect of vitamin E on salivary glands after radioiodine therapy for differential thyroid cancer: A randomized-controlled trial  + (Oral, 300mg Duration: week -1 radioiodine treatment until week +4 (total 5 weeks))
• Argyriou et al. (2006): A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results  + (Oral, 300mg, 2x daily Duration: during chemotherapy until 3 months afterwards)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Oral, 320mg daily MA or 500mg daily MPA Oral, 2.2g EPA daily + 2g/daily Resource Support Oral, 2x 2g daily L-Carnitine Oral, 2x 100mg daily Thalidomid Duration: 4 month)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (Oral, 320mg daily MA or 500mg daily MPA Duration: 4 month)
• Shamsaei et al. (2017): The Vitamin E Preventive Effect on Taxol-Induced Neuropathy Among Patients With Breast Cancer: A Randomized Clinical Trial  + (Oral, 400 IU daily Duration: length of study)
• Shamsaei et al. (2017): The Vitamin E Preventive Effect on Taxol-Induced Neuropathy Among Patients With Breast Cancer: A Randomized Clinical Trial  + (Oral, 400 IU daily Duration: length of study)
• Mazdak et al. (2012): Vitamin E reduces superficial bladder cancer recurrence: A randomized controlled Trial  + (Oral, 400IU, 1x daily)
• Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial  + (Oral, 400mg daily Start: after randomization prior to chemotherapy Duration: until 3 months post-CTX)
• Villani et al. (2016): Vitamin E neuroprotection against cisplatin ototoxicity: Preliminary results from a randomized, placebo-controlled trial  + (Oral, 400mg daily Start: after randomization prior to chemotherapy Duration: until 3 months post-CTX)
• Ghoreishi et al. (2007): Effect of vitamin E on chemotherapy-induced mucositis and neutropenia in leukemic patients undergoing bone marrow transplantation  + (Oral, 400mg, 2x daily Start: day -7 surgery Duration: until day 28 after surgery)
• Fallahi et al. (2013): Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer?  + (Oral, 800 IU per day Start: Week -1 radioiodine therapy to 4 weeks after Duration: 5 weeks)
• Jatoi et al. (2002): Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study  + (Oral, 800mg/day liquid + placebo)
• Mondal et al. (2014): Comparative study among glutamine, acetyl-L-carnitine, vitamin-E and methylcobalamine for treatment of paclitaxel-induced peripheral neuropathy  + (Oral, day 0 chemotherapy: 500 µg 3x daily Duration: until 1 month after the end of chemotherapy)
• Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer  + (Orally rinsed with Polaprezinc solution (P … Orally rinsed with Polaprezinc solution (Polaprezinc granules (0.5g) were dissolved in 20 ml of 5% sodium alginate solution, a natural thickener used as food additive, by agitating intermittently for 1 hr) for 3 min 4 times in a day, the solution was swallowed after oral rinse;</br>Duration: from the start to the end of the radiotherapym the start to the end of the radiotherapy)
• Watanabe et al. (2010): Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer  + (Orally rinsed with azulene solution (prepared by pouring 7 drops of 4% liquid solution into 100 ml water) for 3 min 4 times in a day; Duration: from the start to the end of the radiotherapy)
• Hejazi et al. (2013): A pilot clinical trial of radioprotective effects of curcumin supplementation in patients with prostate cancer  + (Orally, 2 capsules 3 times a day (each capsule contained 500mg roasted rice flour) Start: week -1 radiotherapy Duration: until the end of radiotherapy, approx. 9 weeks in total)
• Hejazi et al. (2016): Effect of Curcumin Supplementation During Radiotherapy on Oxidative Status of Patients with Prostate Cancer: A Double Blinded, Randomized, Placebo-Controlled Study  + (Orally, 2 capsules 3 times a day (each capsule contained 500mg roasted rice flour) Start: week -1 radiotherapy Duration: until the end of radiotherapy, approx. 9 weeks in total)
• Stephenson et al. (2000): The Effects of Foot Reflexology on Anxiety and Pain in Patients With Breast and Lung Cancer.  + (Patients served as their own control first and then received reflexology; passive control/no intervention (1x 30 min), at least 48 h break, reflex therapy (1x 30 min))